While the effects of CD8+ CTL and NK cell infiltration should be monitored, SMIs to GSK3 may offer one of the best and most cost-efficient therapies/co-therapies currently available to regulate both inclusion body formation and apoptosis in muscle tissue as well as the chronic inflammatory signaling in IBM. This evidence concerns the gene CD8A and inclusion body myositis.